Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A tablet comprising at least two distinct segments, one segment of which comprises as active ingredient predominantly efletirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine, said segments being composed and formed in such a way that the resulting tablet is substantially free of impurities formed by reaction of efletirizine with pseudoephedrine, and with the proviso that the tablet comprises less than 5 % by weight, relative to the total weight of the pseudoephedrine segment, of an alkalinizing agent.

2. (original) A tablet comprising at least two distinct segments one segment of which comprises as active ingredient predominantly efletirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine, said segments being composed and formed in such a way that the pharmacokinetic profiles of the efletirizine and pseudoephedrine are substantially the same as in a dosage form containing each as sole active ingredient in the same amount.

3. (currently amended) A tablet according to claim 1 ~~or 2~~ wherein the pseudoephedrine segment is substantially free of efletirizine.

4. (currently amended) A tablet according to claim 1 ~~or 2~~ wherein the efletirizine segment is substantially free of pseudoephedrine.

5. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the interfacial surface area of the pseudoephedrine segment and efletirizine segment is less than 180 mm^2.

6. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the tablet further comprises a barrier segment wherein said barrier segment separates the efletirizine segment and the pseudoephedrine segment.

7. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the pseudoephedrine segment comprises less than 5 % by weight, relative to the total weight of the pseudoephedrine segment, of an alkalinizing agent.

8-13 (cancelled)

14. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the weight ratio of pseudoephedrine to efletirizine is between 2 and 40.

15. (cancelled)

16. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the pseudoephedrine segment comprises between about 10 and 265 mg of pseudoephedrine and the efletirizine segment comprises between about 3 and 70 mg of efletirizine.

17. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the pseudoephedrine segment is in a slow release form.

18. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the efletirizine is in an immediate release form.

19. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the tablet weight is between 200 to 800 mg.

20. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the tablet comprises an amount of efletirizine which when dosed to a human subject gives a efletirizine area under the plasma efletirizine concentration versus time curve which is between 80 % and 125 % of the area under the plasma efletirizine concentration versus time curve observed when a dihydrochloride efletirizine immediate release tablet comprising said amount of efletirizine is dosed to same human subject at the same efletirizine dose.

21. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the tablet comprises an amount of pseudoephedrine which when dosed to a human subject gives a pseudoephedrine area under the pseudoephedrine plasma concentration versus time curve which is between 80 % and 125 % of the area under the plasma pseudoephedrine

concentration versus time curve observed when a pseudoephedrine sustained release tablet comprising said amount of pseudoephedrine is dosed to same human subject.

22-37 (cancelled)

38. (currently amended) A tablet according to ~~any one of the preceding claims~~ claim 1 wherein the tablet is a bi-layer tablet, the efletirizine segment being a layer and the pseudoephedrine segment being a layer.

39. (original) A tablet according to claim 38 wherein the weight ratio of the pseudoephedrine layer to the efletirizine layer is between 0.25 to 10.

40. (currently amended) A tablet according to claims 38 ~~or 39~~ wherein the outer face of each of the two layers has a different shape.

41. (original) A tablet according to claim 40 wherein the tablet has a first face which is the pseudoephedrine layer, having multiple radii of curvature.

42. (original) A tablet according to claim 40 wherein the tablet has a second face which is the efletirizine layer, having a single radius of curvature.

43. (currently amended) A tablet according to ~~anyone of the preceding claims~~ claim 1 which comprises an additional coating layer.

44. (original) A tablet according to claim 43 wherein the coating layer can act as a taste masking agent.

45-48 (cancelled)